Latest Capital Raises News

Rapid Lithium Ltd has completed its acquisition of Midwest Lithium and initiated a $2 million entitlement offer, marking a strategic pivot towards US and Canadian exploration projects.

Mithril Silver and Gold Limited reports strong drilling results at its Copalquin gold-silver project in Mexico, backed by a $12.5 million placement to fund an expanded 35,000-metre 2025 exploration program.

Papyrus Australia Ltd reported a $284,000 net cash outflow for the December 2024 quarter, reflecting abnormal expenses but maintaining a solid funding runway through existing facilities and strategic initiatives.

Cauldron Energy’s December quarter report highlights a breakthrough uranium discovery at Manyingee South within the Yanrey Project, alongside a successful $4 million capital raise to fund ongoing exploration.

Lode Resources has completed the acquisition of the Montezuma Antimony Project in Tasmania, delivering high-grade drill results that bolster its strategy to become a leading Australian antimony producer amid global supply shortages.

Tolu Minerals reports significant progress in recommencing production and expanding resources at its Tolukuma mine, underpinned by strategic hires and advanced geophysical surveys.

ReNu Energy reports progress on a management buyout proposal for its hydrogen subsidiary and completes sale of legacy geothermal assets, signaling a strategic pivot and ongoing capital challenges.

HITIQ Limited’s largest shareholder, Harmil Angel Investments, is converting $1.6 million in convertible notes into shares, while the company revamps its advisory mandate to attract US investors.

Group 6 Metals Limited reveals a challenging quarter marked by safety incidents and production setbacks at its Dolphin Tungsten Mine, while initiating a major recapitalisation plan to stabilise finances and leadership.

Audio Pixels Holdings Limited reports significant technical progress in its Digital Sound Reconstruction technology and secures additional funding through convertible notes, while continuing to navigate ASX suspension challenges.

Chimeric Therapeutics has dosed the first three patients in its Phase 1/2 CHM CDH17 CAR-T trial targeting gastrointestinal cancers, alongside advancing its AML and NK cell therapy programs. The company also secured $5 million in funding and appointed Dr Rebecca McQualter as CEO.

Dotz Nano Limited has landed its first commercial order for DotzShield in the U.S. and made significant strides in carbon capture technology development, including a new sorbent for Direct Air Capture and a strategic collaboration with Bar-Ilan University.